Sort
64,565 grants matching “drug discovery”
Testing of Drug Combinations For Mycobacterium tuberculosis (MTB) in Mice
$1,250,319Richard Slayden · Colorado State University · N01 · FY2022 · AI
India International Center for Excellence in Research
$1,250,220Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Stanford Technology Accelerating Medicines Partnership Center
$1,250,001William H Robinson · Stanford University · UH2 · FY2015 · AR
PharmGKB: pharmacogenomics discovery and implementation
$1,250,000Russ Biagio Altman · Stanford University · U24 · FY2020 · HG
Nephrotic Syndrome Rare Disease Clinical Research Network
$1,250,000Matthias Kretzler · University Of Michigan At Ann Arbor · U54 · FY2014 · DK
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
$1,250,000Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2019 · AG
Clinical and Translational Science Award
$1,250,000Reza Shaker · Medical College Of Wisconsin · UL1 · FY2021 · TR
PharmGKB: pharmacogenomics discovery and implementation
$1,250,000Russ Biagio Altman · Stanford University · U24 · FY2021 · HG
PharmGKB: pharmacogenomics discovery and implementation
$1,250,000Teri Ellen Klein · Stanford University · U24 · FY2022 · HG
Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease
$1,249,999Milton L Greenberg · Vivreon Biosciences, Llc · R44 · FY2020 · AG
SBIR Phase II: Development of an Intracellular Delivery Platform for Accelerated Drug Discovery Using Genetically Engineered Human Immune Cells
$1,249,996Marija Tadin-Strapps · Sqz Biotechnologies Company · · FY2016 · TIP
Signaling Aberrations and Cerebral Cavernous Malformation Pathogenesis
$1,249,844Douglas A Marchuk · Duke University · P01 · FY2024 · NS
NICHD: R&D: ESSENTIAL STUDIES AND MANUFACTURE FOR CURRENT PRODUCTS IN ONGOING CLINICAL DEVELOPMENT: NON-SEVERABLE
$1,249,426Deborah Bunin · Sri International · N01 · FY2025 · HD
Center of Excellence for High Throughput Proteogenomic Characterization
$1,249,405Steven A. Carr · Broad Institute, Inc. · U24 · FY2019 · CA
Cancer Center Support Grant
$1,249,351Jennifer A Pietenpol · Vanderbilt University · P30 · FY2010 · CA
Functional genomics and DEC-Tec to identify germ cell-specific contraceptives
$1,249,287Martin M Matzuk · Baylor College Of Medicine · P01 · FY2017 · HD
Transcription and Therapy for HD: from Molecules to Man
$1,249,142Massachusetts General Hospital · P01 · FY2005 · NS
VICKtOrY Early Clinical Trials Consortium
$1,249,062Patricia M Lorusso · Yale University · UM1 · FY2025 · CA
Defining and Manipulating Epigenomic Regulators in Endogenous Systems
$1,248,825Jordan Leslie Meier · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Washington University PDX Development and Trial Center
$1,248,813Ramaswamy Govindan · Washington University · U54 · FY2019 · CA
High content screening system - Perkin Elmer Opera Phenix Plus
$1,248,729Jennifer C Fung · University Of California, San Francisco · S10 · FY2024 · OD
Discovery of new cellular targets for small-molecule inhibition of enveloped vir
$1,248,634Sean P. J. Whelan · Harvard Medical School · U19 · FY2017 · AI
Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML
$1,248,330Jeffrey Wallace Tyner · Oregon Health & Science University · U54 · FY2019 · CA
Transcription and Therapy for HD: from Molecules to Man
$1,248,267Massachusetts General Hospital · P01 · FY2004 · NS
Innovative Approaches for Cocaine Pharmacotherapy
$1,248,237Helen M Pettinati · University Of Pennsylvania · P50 · FY2007 · DA